JP2016538316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538316A5 JP2016538316A5 JP2016536372A JP2016536372A JP2016538316A5 JP 2016538316 A5 JP2016538316 A5 JP 2016538316A5 JP 2016536372 A JP2016536372 A JP 2016536372A JP 2016536372 A JP2016536372 A JP 2016536372A JP 2016538316 A5 JP2016538316 A5 JP 2016538316A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- compound
- unsubstituted
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 58
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000003107 substituted aryl group Chemical group 0.000 claims 16
- -1 -O- carboxy Chemical group 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 108010050904 Interferons Proteins 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 3
- MTPVBMVUENFFLL-HXUWFJFHSA-N 1-(2-fluorophenyl)-3-[(3s)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]urea Chemical compound FC1=CC=CC=C1NC(=O)N[C@@H]1C(=O)NC2=CC=CC=C2C(C=2C=CC=CC=2)=N1 MTPVBMVUENFFLL-HXUWFJFHSA-N 0.000 claims 2
- SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 claims 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims 2
- KSHJXDWYTZJUEI-UHFFFAOYSA-N 1-cyclopropyl-3-[[1-(4-hydroxybutyl)benzimidazol-2-yl]methyl]imidazo[4,5-c]pyridin-2-one Chemical compound N=1C2=CC=CC=C2N(CCCCO)C=1CN(C1=O)C2=CN=CC=C2N1C1CC1 KSHJXDWYTZJUEI-UHFFFAOYSA-N 0.000 claims 2
- RDQSNNMSDOHAPG-UHFFFAOYSA-N 2-[[2-[[1-(2-aminoethyl)piperidin-4-yl]amino]-4-methylbenzimidazol-1-yl]methyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C(CN2C3=CC=CC(C)=C3N=C2NC2CCN(CCN)CC2)=N1 RDQSNNMSDOHAPG-UHFFFAOYSA-N 0.000 claims 2
- DKORMNNYNRPTBJ-UHFFFAOYSA-N 2-[[6-[[2-(3-hydroxypropyl)-5-methylanilino]methyl]-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol Chemical compound CC1=CC=C(CCCO)C(NCC=2C=C3N(CC=4C(=CC=C(C)N=4)O)C(NCCCN4CCOCC4)=NC3=CC=2)=C1 DKORMNNYNRPTBJ-UHFFFAOYSA-N 0.000 claims 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims 2
- ZETYKEPFFRMVBX-UHFFFAOYSA-N rfi 641 Chemical compound NC(=O)CN(CC(N)=O)S(=O)(=O)C1=CC=CC(NC=2N=C(NC=3C=C(C(C=4C(=CC(NC=5N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=C(NC=6C=C(C=CC=6)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=5)=CC=4)S(O)(=O)=O)=CC=3)S(O)(=O)=O)N=C(NC=3C=C(C=CC=3)S(=O)(=O)N(CC(N)=O)CC(N)=O)N=2)=C1 ZETYKEPFFRMVBX-UHFFFAOYSA-N 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 229950006081 taribavirin Drugs 0.000 claims 2
- BSDIOOGSAAJMSR-JOCHJYFZSA-N (9br)-9b-(4-chlorophenyl)-1-(4-fluorobenzoyl)-2,3-dihydroimidazo[5,6]pyrrolo[1,2-a]pyridin-5-one Chemical compound C1=CC(F)=CC=C1C(=O)N1[C@@]2(C=3C=CC(Cl)=CC=3)C3=CN=CC=C3C(=O)N2CC1 BSDIOOGSAAJMSR-JOCHJYFZSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- ASILHPOFVOONEE-UHFFFAOYSA-N 1,4-bis(3-methylpyridin-4-yl)-1,4-diazepane Chemical compound CC1=CN=CC=C1N1CCN(C=2C(=CN=CC=2)C)CCC1 ASILHPOFVOONEE-UHFFFAOYSA-N 0.000 claims 1
- GVVIAZOBDFNZPB-UHFFFAOYSA-N 1h-1-benzazepine-2-carboxamide Chemical compound N1C(C(=O)N)=CC=CC2=CC=CC=C21 GVVIAZOBDFNZPB-UHFFFAOYSA-N 0.000 claims 1
- BLUJRJMLDHEMRX-UHFFFAOYSA-N 2-[[2-hydroxy-5-[(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1N=Cc1ccc(O)c(c1)C(c1ccc(O)cc1)c1cc(C=Nn2nnnc2C)ccc1O BLUJRJMLDHEMRX-UHFFFAOYSA-N 0.000 claims 1
- BLUJRJMLDHEMRX-BMNRKXRESA-N 2-[[2-hydroxy-5-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenyl]-(4-hydroxyphenyl)methyl]-4-[(E)-(5-methyltetrazol-1-yl)iminomethyl]phenol Chemical compound Cc1nnnn1\N=C\c2ccc(O)c(c2)C(c3ccc(O)cc3)c4cc(\C=N\n5nnnc5C)ccc4O BLUJRJMLDHEMRX-BMNRKXRESA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- LNZKOJMCKWERFO-UHFFFAOYSA-N 2H-thieno[2,3-d]azepine-2-carboxamide Chemical compound S1C(C=C2C1=CC=NC=C2)C(=O)N LNZKOJMCKWERFO-UHFFFAOYSA-N 0.000 claims 1
- OPRZZDKUMMSNLY-UHFFFAOYSA-N 4-amino-8-[3-[2-(3,4-dimethoxyphenyl)ethylamino]propyl]-6,6-dimethyl-2-(4-methyl-3-nitrophenyl)-3h-imidazo[4,5-h]isoquinoline-7,9-dione Chemical compound C1=C(OC)C(OC)=CC=C1CCNCCCN1C(=O)C(C)(C)C(C=C(N)C2=C3NC(=N2)C=2C=C(C(C)=CC=2)[N+]([O-])=O)=C3C1=O OPRZZDKUMMSNLY-UHFFFAOYSA-N 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 229940127513 Fusion Protein Inhibitors Drugs 0.000 claims 1
- 108091006027 G proteins Proteins 0.000 claims 1
- 102000030782 GTP binding Human genes 0.000 claims 1
- 108091000058 GTP-Binding Proteins 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 1
- QDZAXMSTRRUTQH-UHFFFAOYSA-N NC1=NN=NN1N=CC1(C(C=CC=C1)C(C1=CC=C(C=C1)O)C1=C(C=CC=C1)O)O Chemical compound NC1=NN=NN1N=CC1(C(C=CC=C1)C(C1=CC=C(C=C1)O)C1=C(C=CC=C1)O)O QDZAXMSTRRUTQH-UHFFFAOYSA-N 0.000 claims 1
- 101710141454 Nucleoprotein Proteins 0.000 claims 1
- YDITYPFXLDVVDY-UHFFFAOYSA-N O=C(NC1CC1)C1=CC2=C(C1)c1ccccc1N(CC2)C(=O)c1ccc(NC(=O)c2ccccc2N2CCCC2)cc1 Chemical compound O=C(NC1CC1)C1=CC2=C(C1)c1ccccc1N(CC2)C(=O)c1ccc(NC(=O)c2ccccc2N2CCCC2)cc1 YDITYPFXLDVVDY-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- YUCHAYRHHXJNQK-UHFFFAOYSA-N amitivir Chemical compound N#CNC1=NN=CS1 YUCHAYRHHXJNQK-UHFFFAOYSA-N 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N benzofuran Natural products C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 150000001907 coumarones Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940125777 fusion inhibitor Drugs 0.000 claims 1
- 102000055576 human SCGB1A1 Human genes 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 150000002475 indoles Chemical class 0.000 claims 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229960001521 motavizumab Drugs 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- XESARGFCSKSFID-FLLFQEBCSA-N pirazofurin Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- PMAKDNHZVBVWFM-UHFFFAOYSA-N sodium;cyano(1,3,4-thiadiazol-2-yl)azanide Chemical compound [Na+].N#C[N-]C1=NN=CS1 PMAKDNHZVBVWFM-UHFFFAOYSA-N 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868519P | 2013-08-21 | 2013-08-21 | |
| US61/868,519 | 2013-08-21 | ||
| US201461945048P | 2014-02-26 | 2014-02-26 | |
| US61/945,048 | 2014-02-26 | ||
| PCT/US2014/051642 WO2015026792A1 (en) | 2013-08-21 | 2014-08-19 | Antiviral compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016538316A JP2016538316A (ja) | 2016-12-08 |
| JP2016538316A5 true JP2016538316A5 (enExample) | 2017-09-28 |
| JP6485817B2 JP6485817B2 (ja) | 2019-03-20 |
Family
ID=52484091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536372A Expired - Fee Related JP6485817B2 (ja) | 2013-08-21 | 2014-08-19 | 抗ウイルス化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20150065504A1 (enExample) |
| EP (1) | EP3036220A4 (enExample) |
| JP (1) | JP6485817B2 (enExample) |
| KR (1) | KR102455034B1 (enExample) |
| CN (2) | CN114716426A (enExample) |
| AU (1) | AU2014308991B2 (enExample) |
| BR (1) | BR112016003348B1 (enExample) |
| CA (1) | CA2921294C (enExample) |
| CL (1) | CL2016000381A1 (enExample) |
| EA (1) | EA038819B1 (enExample) |
| HK (1) | HK1225716A1 (enExample) |
| IL (1) | IL244163A0 (enExample) |
| MX (2) | MX2016002199A (enExample) |
| NZ (1) | NZ716822A (enExample) |
| PE (1) | PE20160547A1 (enExample) |
| PH (2) | PH12021550330A1 (enExample) |
| SG (1) | SG11201600977XA (enExample) |
| TW (1) | TWI646080B (enExample) |
| UA (1) | UA123854C2 (enExample) |
| WO (1) | WO2015026792A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| US9243022B2 (en) | 2012-12-21 | 2016-01-26 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CA2921294C (en) | 2013-08-21 | 2023-05-16 | Alios Biopharma, Inc. | Antiviral compounds |
| MA40404A (fr) * | 2014-08-05 | 2017-06-14 | Alios Biopharma Inc | Polythérapie pour traiter un paramyxovirus |
| MA41614A (fr) * | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
| CN109734651A (zh) * | 2015-07-06 | 2019-05-10 | 江苏恩华药业股份有限公司 | 阿芬太尼、舒芬太尼的制备方法及用于制备阿芬太尼、舒芬太尼的化合物 |
| MY197231A (en) | 2015-07-22 | 2023-06-06 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| EP4327809A3 (en) * | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| CN108699077B (zh) * | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
| ES2877808T3 (es) * | 2016-02-03 | 2021-11-17 | Janssen Sciences Ireland Unlimited Co | Producto combinado para tratar o mejorar una infección por virus respiratorio sincicial |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| EP3522719A1 (en) * | 2016-10-05 | 2019-08-14 | Syngenta Participations AG | Methods of preserving the biological activity of ribonucleic acids |
| WO2018129287A1 (en) | 2017-01-06 | 2018-07-12 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as rsv inhibitors |
| WO2018152413A1 (en) | 2017-02-16 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
| WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
| WO2019006295A1 (en) * | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| US10851115B2 (en) | 2017-06-30 | 2020-12-01 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| CN111386118B (zh) | 2017-09-29 | 2023-05-09 | 英安塔制药有限公司 | 作为rsv抑制剂的组合药物剂 |
| WO2019094920A1 (en) | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as rsv inhibitors |
| MX394621B (es) | 2017-11-13 | 2025-03-24 | Enanta Pharm Inc | Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona |
| HUE069183T2 (hu) | 2018-02-28 | 2025-02-28 | Novartis Ag | 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H--pirrolo[1',2':4,5]pirazino[1,2-b]piridazin-3,5-dion származékok és kapcsolódó vegyületek mint orthomyxovírus repikáció gátlók influenza kezelésére |
| WO2019199908A1 (en) | 2018-04-11 | 2019-10-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
| WO2020190935A1 (en) | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
| US11179400B2 (en) | 2019-04-09 | 2021-11-23 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
| CN110105268A (zh) * | 2019-05-30 | 2019-08-09 | 西安交通大学 | 一种戊内酰胺生物碱类化合物的合成方法 |
| PH12022550783A1 (en) * | 2019-10-04 | 2023-07-31 | Enanta Pharm Inc | Antiviral heterocyclic compounds |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| WO2021198981A1 (en) | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Antiviral compounds and uses thereof |
| AU2021260799A1 (en) * | 2020-04-21 | 2023-01-05 | Janssen Sciences Ireland Unlimited Company | RSV inhibiting 3-substituted quinoline and cinnoline derivatives |
| WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
| WO2022086840A1 (en) * | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| TWI839652B (zh) | 2020-10-28 | 2024-04-21 | 日商鹽野義製藥股份有限公司 | 具有抗病毒活性的醯胺衍生物 |
| MX2023009961A (es) | 2021-02-26 | 2023-09-05 | Enanta Pharm Inc | Compuestos heterociclicos antivirales. |
| US12612412B2 (en) | 2021-02-26 | 2026-04-28 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| WO2022211812A1 (en) * | 2021-04-01 | 2022-10-06 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| WO2023052593A1 (en) | 2021-10-01 | 2023-04-06 | Janssen Sciences Ireland Unlimited Company | Rsv inhibiting spiro bearing derivatives |
| CN113788764B (zh) * | 2021-10-20 | 2024-02-02 | 江苏弘和药物研发有限公司 | 一种坦伯酰胺的合成方法 |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2023237732A1 (en) | 2022-06-10 | 2023-12-14 | Janssen Sciences Ireland Unlimited Company | Rsv inhibiting triazolo bearing derivatives |
| WO2023237730A1 (en) | 2022-06-10 | 2023-12-14 | Janssen Sciences Ireland Unlimited Company | Rsv inhibiting triazolo and spiro bearing derivatives |
| EP4382529A1 (en) | 2022-12-07 | 2024-06-12 | Bayer Consumer Care AG | A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
| US20250066323A1 (en) * | 2023-08-17 | 2025-02-27 | Merck Sharp & Dohme Llc | Inhibitors of human respiratory syncytial virus and metapneumovirus |
| CN122079876B (zh) * | 2026-04-22 | 2026-08-04 | 湖南速博生物技术有限公司 | 一种氟吡菌酰胺的合成方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1276808A (en) * | 1916-12-07 | 1918-08-27 | Alexander N Pierman | Signal or alarm apparatus. |
| US2516098A (en) * | 1949-03-26 | 1950-07-25 | Parke Davis & Co | Biphenyl compounds |
| WO1984002907A1 (en) | 1983-01-21 | 1984-08-02 | Alkaloida Vegyeszeti Gyar | New alkyl diamine derivatives |
| US4876346A (en) * | 1985-05-02 | 1989-10-24 | American Home Products Corporation | Quinoline compounds |
| FI97540C (fi) * | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
| MA26487A1 (fr) | 1997-04-29 | 2004-12-20 | Smithkline Beecham Corp | Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant . |
| US6410585B1 (en) | 1997-08-28 | 2002-06-25 | Scott D. Larsen | Inhibitors of protein tyrosine phosphatase |
| BR9910621A (pt) * | 1998-05-22 | 2001-01-30 | Smithkline Beecham Corp | Novos compostos de imidazol 2-alquil substituìdos |
| AR018915A1 (es) | 1998-06-24 | 2001-12-12 | Smithkline Beecham Corp | Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos |
| US6623741B1 (en) | 2000-02-29 | 2003-09-23 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission |
| KR20030034184A (ko) | 2000-09-15 | 2003-05-01 | 아노르메드 인코포레이티드 | 케모킨 수용체 결합 헤테로사이클릭 화합물 |
| US6982348B2 (en) | 2001-01-26 | 2006-01-03 | Takeda Pharmaceutical Company Limited | Aminoethanol derivatives |
| JP2002293764A (ja) * | 2001-01-26 | 2002-10-09 | Takeda Chem Ind Ltd | アミノエタノール誘導体 |
| US6878743B2 (en) * | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| DE60234264D1 (de) * | 2001-10-01 | 2009-12-17 | Bristol Myers Squibb Co | Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen |
| GB0128415D0 (en) * | 2001-11-27 | 2002-01-16 | Univ Sheffield | Medicaments |
| AU2003269413A1 (en) | 2002-11-01 | 2004-05-25 | Pharmacia & Upjohn Company Llc | Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy |
| CN1863770B (zh) | 2003-08-08 | 2011-05-25 | 先灵公司 | 具有杂环取代基的环胺base-1抑制剂 |
| CA2534950A1 (en) * | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| US7598412B2 (en) * | 2003-10-08 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| WO2005042530A1 (en) | 2003-10-30 | 2005-05-12 | Boehringer Ingelheim (Canada) Ltd. | Rsv polymerase inhibitors |
| ATE435222T1 (de) | 2003-12-18 | 2009-07-15 | Tibotec Pharm Ltd | Aminobenzimidazole und benzimidazole als inhibitoren der replikation von respiratory syncytial virus |
| EP1729772B8 (en) * | 2004-03-24 | 2017-04-19 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine glycine transporter inhibitors |
| GB0425919D0 (en) * | 2004-11-25 | 2004-12-29 | Prosidion Ltd | Indole-2-carboxylic acid amides |
| AU2006260969B2 (en) | 2005-06-20 | 2011-11-17 | Janssen Sciences Ireland Uc | 1- ( 2-amino-3- (substituted alkyl)-3H-benzimidazolylmethyl) -3-substituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus |
| US20110207771A1 (en) * | 2006-06-08 | 2011-08-25 | Syngenta Crop Protection, Inc. | N-(l-alkyl-2-phenylethyl)-carboxamide derivatives and use thereof as fungicides |
| CN100509766C (zh) | 2006-06-19 | 2009-07-08 | 张文 | 羟基和氨基同时保护的手性非α-氨基酸衍生物的制备方法 |
| WO2008098239A2 (en) | 2007-02-09 | 2008-08-14 | Emory University | Paramyxovirus family inhibitors and methods of use thereof |
| EP2594565B1 (en) * | 2007-05-31 | 2018-10-24 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| JP2010531358A (ja) | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体 |
| BRPI0815042A2 (pt) | 2007-08-01 | 2015-02-10 | Pfizer | Compostos de pirazol |
| KR101640263B1 (ko) * | 2007-10-05 | 2016-07-15 | 젠자임 코포레이션 | 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법 |
| SI2074120T1 (sl) | 2007-10-25 | 2010-06-30 | Exelixis Inc | Tropan spojine |
| NZ585784A (en) | 2007-12-13 | 2012-09-28 | Alnylam Pharmaceuticals Inc | siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection |
| JP5587790B2 (ja) * | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
| TW201000099A (en) | 2008-06-20 | 2010-01-01 | Amgen Inc | S1P1 receptor agonists and use thereof |
| US20100278835A1 (en) | 2009-03-10 | 2010-11-04 | Astrazeneca Uk Limited | Novel compounds 660 |
| US8791299B2 (en) * | 2009-05-20 | 2014-07-29 | Universite Laval | Compounds for the inhibition of herpes viruses |
| CN102459332B (zh) | 2009-06-05 | 2015-08-19 | 埃博灵克斯股份有限公司 | 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体 |
| RU2012102094A (ru) * | 2009-06-26 | 2013-08-10 | Панацеа Биотек Лтд. | Новые азабициклогексаны |
| WO2011005842A1 (en) * | 2009-07-09 | 2011-01-13 | Gilead Sciences, Inc. | Anti-rsv compounds |
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| KR101781663B1 (ko) * | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| US9050065B2 (en) * | 2010-01-20 | 2015-06-09 | Micro Interventional Devices, Inc. | Tissue repair implant and delivery device and method |
| WO2011097607A1 (en) * | 2010-02-08 | 2011-08-11 | Southern Research Institute | Anti-viral treatment and assay to screen for anti-viral agent |
| CN102958933B (zh) | 2010-06-24 | 2016-02-03 | 吉里德科学公司 | 作为抗病毒药的吡唑并[1,5-a]嘧啶类 |
| WO2012020786A1 (ja) | 2010-08-11 | 2012-02-16 | 日本新薬株式会社 | 医薬組成物 |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| US8796303B2 (en) | 2010-11-26 | 2014-08-05 | Biota Scientific Management Pty Ltd. | Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections |
| TWI527814B (zh) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類 |
| TWI541241B (zh) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類 |
| TWI501967B (zh) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類 |
| TWI515187B (zh) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | 作為呼吸道融合病毒抗病毒劑之吲哚類 |
| TWI530495B (zh) | 2010-12-16 | 2016-04-21 | 健生科學愛爾蘭無限公司 | 苯并咪唑呼吸道融合病毒抑制劑 |
| DE102011106990B3 (de) | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| JP2014530225A (ja) | 2011-10-11 | 2014-11-17 | エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス疾患の処置および予防のための化合物 |
| SG11201401342VA (en) | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| US8961959B2 (en) * | 2011-10-17 | 2015-02-24 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| US20140287916A1 (en) * | 2011-11-04 | 2014-09-25 | Syngenta Participations Ag | Pesticidal compounds |
| ES2647486T3 (es) | 2011-12-22 | 2017-12-21 | Gilead Sciences, Inc. | Pirazolo[1,5-a]pirimidinas como agentes antivirales |
| JP5348267B2 (ja) * | 2012-03-06 | 2013-11-20 | 住友金属鉱山株式会社 | 脱亜鉛処理プラント及び脱亜鉛プラントの操業方法、並びにニッケル酸化鉱石の湿式製錬方法 |
| EA027855B1 (ru) | 2012-04-17 | 2017-09-29 | Гайлид Сайэнсиз, Инк. | Соединения и способы для противовирусной терапии |
| WO2013186334A1 (en) | 2012-06-15 | 2013-12-19 | Janssen R&D Ireland | 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents |
| JP2015519387A (ja) | 2012-06-15 | 2015-07-09 | ヤンセン・アールアンドデイ・アイルランド | Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体 |
| JP2015519385A (ja) | 2012-06-15 | 2015-07-09 | ヤンセン・アールアンドデイ・アイルランド | Ｒｓウイルス抗ウイルス薬としての、ベンゾイミダゾールによって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体 |
| CA2873920C (en) | 2012-06-15 | 2021-07-20 | Janssen R&D Ireland | 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents |
| BR112015000392A2 (pt) | 2012-07-10 | 2017-06-27 | Hoffmann La Roche | novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório |
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| CA2921294C (en) | 2013-08-21 | 2023-05-16 | Alios Biopharma, Inc. | Antiviral compounds |
| MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
-
2014
- 2014-08-19 CA CA2921294A patent/CA2921294C/en active Active
- 2014-08-19 KR KR1020167007035A patent/KR102455034B1/ko not_active Expired - Fee Related
- 2014-08-19 CN CN202210267361.7A patent/CN114716426A/zh active Pending
- 2014-08-19 WO PCT/US2014/051642 patent/WO2015026792A1/en not_active Ceased
- 2014-08-19 SG SG11201600977XA patent/SG11201600977XA/en unknown
- 2014-08-19 JP JP2016536372A patent/JP6485817B2/ja not_active Expired - Fee Related
- 2014-08-19 EA EA201690224A patent/EA038819B1/ru unknown
- 2014-08-19 PE PE2016000288A patent/PE20160547A1/es not_active Application Discontinuation
- 2014-08-19 HK HK16113922.8A patent/HK1225716A1/zh unknown
- 2014-08-19 MX MX2016002199A patent/MX2016002199A/es unknown
- 2014-08-19 CN CN201480055176.5A patent/CN105636936B/zh not_active Expired - Fee Related
- 2014-08-19 AU AU2014308991A patent/AU2014308991B2/en not_active Ceased
- 2014-08-19 BR BR112016003348-5A patent/BR112016003348B1/pt not_active IP Right Cessation
- 2014-08-19 UA UAA201601391A patent/UA123854C2/uk unknown
- 2014-08-19 NZ NZ716822A patent/NZ716822A/en not_active IP Right Cessation
- 2014-08-19 EP EP14837913.4A patent/EP3036220A4/en not_active Withdrawn
- 2014-08-19 PH PH1/2021/550330A patent/PH12021550330A1/en unknown
- 2014-08-19 US US14/462,937 patent/US20150065504A1/en not_active Abandoned
- 2014-08-21 TW TW103128871A patent/TWI646080B/zh not_active IP Right Cessation
-
2016
- 2016-02-17 IL IL244163A patent/IL244163A0/en unknown
- 2016-02-18 PH PH12016500332A patent/PH12016500332B1/en unknown
- 2016-02-19 CL CL2016000381A patent/CL2016000381A1/es unknown
- 2016-02-19 MX MX2021002168A patent/MX2021002168A/es unknown
-
2017
- 2017-08-16 US US15/678,901 patent/US20180065932A1/en not_active Abandoned
-
2018
- 2018-10-19 US US16/165,865 patent/US11021444B2/en not_active Expired - Fee Related
-
2021
- 2021-03-22 US US17/208,964 patent/US20220363640A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507861A5 (enExample) | ||
| JP7654071B2 (ja) | 複素環スピロ化合物及び使用方法 | |
| AU2010315126B2 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| CN118974055A (zh) | 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途 | |
| JP7860103B2 (ja) | 複素環式スピロ化合物及びその使用方法 | |
| RU2017106742A (ru) | Комбинированная терапия для лечения парамиксовируса | |
| JP2022184886A5 (enExample) | ||
| JP2025535046A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質の複素環阻害剤及びその使用 | |
| JP2022184886A (ja) | Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬 | |
| CA2781287C (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2020504136A5 (enExample) | ||
| JP2019535664A5 (enExample) | ||
| RS54510B1 (sr) | Imidazotriazini i imidazopirimidini kao inhibitori kinaze | |
| JP2015511245A5 (enExample) | ||
| JP2016028073A (ja) | キナーゼ調節のための化合物および方法、ならびにそれらの適応症 | |
| JP2011507854A5 (enExample) | ||
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| HUP0400718A2 (hu) | PDE7 és PDE4 kettős inhibitorok alkalmazása leukocita aktivitással társult betegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
| MD3468971T2 (ro) | Noi derivați de piperidinil (hetero)aril-substituiţi, procedeu de obţinere a acestora și compoziții farmaceutice care îi conțin | |
| JP2014506929A5 (enExample) | ||
| CA3166246A1 (en) | Substituted 1,1'-biphenyl compounds and methods using same | |
| JP2014511355A5 (enExample) | ||
| JP2024536858A5 (enExample) | ||
| JP2017535536A5 (enExample) | ||
| JP2023539985A5 (enExample) |